Most veteran investors can attest that, although they're also often a complete bust, every now and then a biopharma stock ...

Viking Therapeutics (NASDAQ: VKTX) has outperformed the market over the past 10 years by 19.49% on an annualized basis producing an average annual return of 33.01%. Currently, Viking Therapeutics has ...

Viking expects to advance the oral version of its experimental obesity drug VK2735 into late-stage study in the third quarter of 2026. ・The subcutaneous formulation of VK2735 is currently in ...

Viking Therapeutics (NASDAQ: VKTX) is aiming to join one of the biggest growth industries of the times: the weight loss drug ...

Viking Therapeutics, Inc. aces hurdles for obesity drug VK2735 vs. Zepbound/Wegovy—tolerability, weak differentiation, and ...

For the quarter ended December, Viking is expected to report a loss per share of $0.91, compared to the loss of $0.32 reported in the corresponding quarter of 2024, ・The subcutaneous formulation of ...

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets ...

Investors in Viking Therapeutics Inc (Symbol: VKTX) saw new options begin trading this week, for the May 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to ...

Piper Sandler analyst Biren Amin maintained a Buy rating on Viking Therapeutics today and set a price target of $71.00. Amin covers the Healthcare sector, focusing on stocks such as Ocular Therapeutix ...

Viking Therapeutics (VKTX) stock jumps as Wall Street welcomes the company's Q4 2025 results which includes pipeline updates on its obesity drug, VK2735. Read more here.

Investors in Viking Therapeutics Inc (Symbol: VKTX) saw new options begin trading this week, for the December 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...